Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.40 |
| ▸ | JAK2 | O60674 | 10/20 | 0.36 |
| ▸ | JAK1 | P23458 | 10/20 | 0.36 |
| ▸ | JAK3 | P52333 | 10/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371116 | 0.87 | JAK2 (0.50) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1370431 | 0.86 | DGAT1 (0.39) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1352358 | 0.86 | DGAT1 (0.43) | DGAT1JAK2JAK1JAK3MAPT | |
| SCHEMBL1369626 | 0.85 | PDE10A (0.41) | DGAT1JAK2JAK1JAK3TYK2 | |
| SCHEMBL1368764 | 0.85 | JAK2 (0.56) | DGAT1JAK2JAK1JAK3TYK2 | |
| SCHEMBL1371598 | 0.85 | JAK2 (0.56) | DGAT1JAK2JAK1JAK3TYK2 | |
| SCHEMBL1352450 | 0.85 | DGAT1 (0.39) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL19646533 | 0.84 | JAK2 (0.43) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2384374 | 0.84 | JAK2 (0.43) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2384364 | 0.84 | JAK2 (0.43) | DGAT1JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481541-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2550274-A1 | PYRROLOPYRAZINE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117160-A1 | PYRROLOPYRAZINE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230414-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | DGAT1 4769/4885JAK2 3/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.